CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 59 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,357,000 | -9.9% | 57,988 | -6.6% | 0.00% | 0.0% |
| Q1 2024 | $2,616,000 | -1.7% | 62,076 | -1.6% | 0.00% | 0.0% |
| Q4 2023 | $2,660,000 | +63.7% | 63,076 | -15.1% | 0.00% | +33.3% |
| Q3 2023 | $1,625,000 | -31.2% | 74,288 | +0.3% | 0.00% | -40.0% |
| Q2 2023 | $2,361,000 | +30.6% | 74,038 | -0.7% | 0.01% | +25.0% |
| Q1 2023 | $1,808,000 | -23.9% | 74,538 | -0.7% | 0.00% | -20.0% |
| Q4 2022 | $2,375,000 | +12.1% | 75,038 | -0.0% | 0.01% | -16.7% |
| Q3 2022 | $2,118,000 | +6.2% | 75,068 | -0.7% | 0.01% | +20.0% |
| Q2 2022 | $1,994,000 | -25.8% | 75,568 | -0.8% | 0.01% | -16.7% |
| Q1 2022 | $2,689,000 | +13.4% | 76,168 | +3.6% | 0.01% | +20.0% |
| Q4 2021 | $2,371,000 | +11.1% | 73,488 | +2.3% | 0.01% | -16.7% |
| Q3 2021 | $2,134,000 | +15.4% | 71,844 | 0.0% | 0.01% | +20.0% |
| Q2 2021 | $1,850,000 | +102.4% | 71,844 | +8.0% | 0.01% | +66.7% |
| Q1 2021 | $914,000 | +21.5% | 66,544 | +46.8% | 0.00% | 0.0% |
| Q4 2020 | $752,000 | – | 45,325 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,965,701,000 | 23.51% |
| Affinity Asset Advisors, LLC | 225,000 | $7,295,000 | 2.65% |
| Perceptive Advisors | 10,173,454 | $329,822,000 | 2.54% |
| Artal Group S.A. | 1,500,000 | $48,630,000 | 1.32% |
| Rock Springs Capital Management LP | 1,648,435 | $53,442,000 | 1.24% |
| RTW INVESTMENTS, LP | 666,666 | $21,613,000 | 0.32% |
| BOULDER HILL CAPITAL MANAGEMENT LP | 8,900 | $289,000 | 0.28% |
| EAM Investors, LLC | 39,907 | $1,294,000 | 0.21% |
| FEDERATED HERMES, INC. | 3,113,333 | $100,934,000 | 0.19% |
| Alkeon Capital Management | 1,909,035 | $61,891,000 | 0.12% |